NL00150012L7 - Common Stock
NAARDEN, the Netherlands and MIAMI, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the...
NAARDEN, The Netherlands and MIAMI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...
-- Reported positive topline data from pivotal Phase 3 BROOKLYN trial evaluating obicetrapib in patients with HeFH; achieved primary endpoint of LS mean...
NAARDEN, The Netherlands and MIAMI, Aug. 02, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...
/PRNewswire/ -- Die Menarini Group gibt heute positive Topline-Daten aus der klinischen Phase-3-Studie BROOKLYN (NCT05425745) bekannt, die von NewAmsterdam...
-- Atteint le critère principal de réduction moyenne de moindre carré du LDL-C en plus des thérapies de modification des lipides aux doses maximales tolérées à...
-Menarini anuncia datos positivos del ensayo clínico fundamental de fase 3 BROOKLYN que evalúa la eficacia, seguridad y tolerabilidad de obicetrapib en...
/PRNewswire/ -- Menarini Group today announces positive topline data from the Phase 3 BROOKLYN clinical trial (NCT05425745) sponsored by NewAmsterdam Pharma...
The company is hoping to use a new mechanism to lower "bad" LDL cholesterol.
Company to host conference call on Monday, July 29 at 8:30 a.m. ET
Company to host conference call on Monday, July 29 at 8:30 a.m. ET...
-- Company expects to report topline data in the first quarter of 2025 --
-- Company expects to report topline data in the first quarter of 2025 --...
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.
NAARDEN, The Netherlands and MIAMI, July 03, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...
NAARDEN, the Netherlands and MIAMI, June 07, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 90,000 of NewAmsterdam’s ordinary shares to five non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
-- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and...
NAARDEN, the Netherlands and MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...
Enrollment to continue to the end of April to accommodate strong patient and site interest
Enrollment to continue to the end of April to accommodate strong patient and site interest...